{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:18:40Z","timestamp":1789402720105,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.msard.2023.104671","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T09:55:46Z","timestamp":1679824546000},"page":"104671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota"],"prefix":"10.1016","volume":"73","author":[{"given":"Silvy","family":"Pilotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zoledziewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"40","key":"10.1016\/j.msard.2023.104671_bib0018","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1073\/pnas.1711233114","article-title":"Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice","volume":"114","author":"Berer","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.msard.2023.104671_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/brainsci10040234","article-title":"Microbiome in multiple sclerosis; where are we, what we know and do not know","volume":"10","author":"Boziki","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.msard.2023.104671_bib0004","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.3748\/wjg.v24.i37.4217","article-title":"Focus on the gut-brain axis: multiple sclerosis, the intestinal barrier and the microbiome","volume":"24","author":"Camara-Lemarroy","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.msard.2023.104671_bib0032","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awy131","article-title":"The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics","volume":"141","author":"Camara-Lemarroy","year":"2018","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2023.104671_bib0036","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/1352458519863133","article-title":"Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity","volume":"26","author":"Camara-Lemarroy","year":"2020","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2023.104671_bib0012","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/JIM.0000000000000192","article-title":"Gut microbiota in multiple sclerosis: possible influence of immunomodulators","volume":"63","author":"Cantarel","year":"2015","journal-title":"J. Investig. Med."},{"key":"10.1016\/j.msard.2023.104671_bib0028","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/872725","article-title":"Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature","volume":"2014","author":"Cao","year":"2014","journal-title":"Gastroenterol. Res. Pract."},{"issue":"7","key":"10.1016\/j.msard.2023.104671_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nrl.2018.04.006","article-title":"The influence of interferon \u03b2-1b on gut microbiota composition in patients with multiple sclerosis","volume":"36","author":"Castillo-\u00c1lvarez","year":"2021","journal-title":"Neurologia (Engl Ed)"},{"key":"10.1016\/j.msard.2023.104671_bib0022","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1073\/pnas.1711235114","article-title":"Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models","volume":"114","author":"Cekanaviciute","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.msard.2023.104671_bib0016","doi-asserted-by":"crossref","first-page":"28484","DOI":"10.1038\/srep28484","article-title":"Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.msard.2023.104671_bib0008","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41582-022-00697-8","article-title":"The role of the gut microbiota in multiple sclerosis","volume":"18","author":"Correale","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2023.104671_bib0021","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1700492","article-title":"High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis","volume":"3","author":"Cosorich","year":"2017","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.msard.2023.104671_bib0019","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ana.26084","article-title":"Gut microbiome in progressive multiple sclerosis","volume":"89","author":"Cox","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.104671_bib0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","article-title":"The gut microbiome in neurological disorders","volume":"19","author":"Cryan","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104671_bib0026","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1038\/cti.2013.11","article-title":"Bacterial lipodipeptide, Lipid 654, is a microbiome-associated biomarker for multiple sclerosis","volume":"2","author":"Farrokhi","year":"2013","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.msard.2023.104671_bib0023","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/B978-0-444-53485-9.00020-9","article-title":"Multiple sclerosis","volume":"135","author":"Filippi","year":"2016","journal-title":"Handb. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.104671_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/apt.14689","article-title":"Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders","volume":"48","author":"Gill","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.msard.2023.104671_bib0033","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.4049\/jimmunol.180.8.5335","article-title":"Sphingosine 1-phosphate regulates the egress of IgA plasmablasts from Peyer's patches for intestinal IgA responses","volume":"180","author":"Gohda","year":"2008","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2023.104671_bib0039","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/s41591-018-0219-z","article-title":"Zhou HW.Regional variation limits applications of healthy gut microbiome reference ranges and disease models","volume":"24","author":"He","year":"2018","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.msard.2023.104671_bib0027","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1128\/IAI.00484-07","article-title":"Respiration of Escherichia coli in the mouse intestine","volume":"75","author":"Jones","year":"2007","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.msard.2023.104671_bib0013","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1212\/NXI.0000000000000517","article-title":"Disease-modifying therapies alter gut microbial composition in MS","volume":"6","author":"Katz Sand","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2023.104671_bib0034","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2006-08-041582","article-title":"Sphingosine 1-phosphate regulates peritoneal B-cell trafficking for subsequent intestinal IgA production","volume":"109","author":"Kunisawa","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.msard.2023.104671_bib0024","doi-asserted-by":"crossref","first-page":"e02513","DOI":"10.1128\/mBio.02513-14","article-title":"Clostridium perfringens epsilon toxin causes selective death of mature oligodendrocytes and central nervous system demyelination","volume":"6","author":"Linden","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.msard.2023.104671_bib0011","first-page":"935","article-title":"Gut-oriented interventions in patients with multiple sclerosis: fact or fiction?","volume":"26","author":"Martinelli","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.msard.2023.104671_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101427","article-title":"The multiple sclerosis gut microbiota: a systematic review","volume":"37","author":"Mirza","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2023.104671_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137429","article-title":"Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to clostridia XIVa and IV clusters","volume":"10","author":"Miyake","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2023.104671_bib0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrgastro.2012.221","article-title":"The digestive neuronal-glial-epithelial unit: a new actor in gut health and disease","volume":"10","author":"Neunlist","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.msard.2023.104671_bib0041","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/JNN.0000000000000252","article-title":"The emerging role of the gut microbiome in adult patients with multiple sclerosis","volume":"48","author":"Newland","year":"2016","journal-title":"J. Neurosci. Nurs."},{"issue":"5","key":"10.1016\/j.msard.2023.104671_bib0025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mi.2010.29","article-title":"A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease","volume":"3","author":"Ochoa-Rep\u00e1raz","year":"2010","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.msard.2023.104671_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","article-title":"Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis","volume":"13","author":"Olsson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104671_bib0031","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3945\/jn.113.180794","article-title":"Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis","volume":"143","author":"Ooi","year":"2013","journal-title":"J. Nutr."},{"issue":"6","key":"10.1016\/j.msard.2023.104671_bib0038","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/TP.0b013e3181b47c61","article-title":"Effect of anti-mouse CD52 monoclonal antibody on mouse intestinal intraepithelial lymphocytes","volume":"88","author":"Qu","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.msard.2023.104671_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/1759091414568185","article-title":"Nutrition facts in multiple sclerosis","volume":"7","author":"Riccio","year":"2015","journal-title":"ASN Neuro"},{"issue":"6371","key":"10.1016\/j.msard.2023.104671_bib0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.msard.2023.104671_bib0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fcimb.2017.00011","article-title":"Oral multiple sclerosis drugs inhibit the in vitro growth of epsilon toxin producing gut bacterium, clostridium perfringens","volume":"7","author":"Rumah","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"issue":"4","key":"10.1016\/j.msard.2023.104671_bib0014","article-title":"Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial","volume":"5","author":"Storm-Larsen","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.104671_bib0001","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104671_bib0017","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ene.13026","article-title":"Gut microbiota in early pediatric multiple sclerosis: a case-control study","volume":"23","author":"Tremlett","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2023.104671_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.645500","article-title":"Lactobacillus reuteri alleviates gastrointestinal toxicity of rituximab by regulating the proinflammatory T Cells in vivo","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"issue":"19","key":"10.1016\/j.msard.2023.104671_bib0020","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1016\/j.cell.2022.08.021","article-title":"Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course","volume":"185","author":"Zhou","year":"2022","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.msard.2023.104671_bib0009","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.autrev.2019.03.016","article-title":"The gut microbiota perspective for interventions in MS","volume":"18","author":"Zoledziewska","year":"2019","journal-title":"Autoimmun. Rev."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482300175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:46Z","timestamp":1761901486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482300175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"alternative-id":["S221103482300175X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104671","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104671"}}